Innate Pharma SA (IPHA) Price Targets From Analysts
Use the tables below to see what analysts covering Innate Pharma SA think about its future price and what recommendations they have for investors and traders.
|Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
Over the past 93 days, IPHA's average price target has gone down $6.54.
Over the past 193 days, IPHA's average upside potential has been 121.76%.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
IPHA Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- The variance in analysts' estimates of IPHA is lower than 5.41% of all US stocks.
- IPHA has a higher upside potential (average analyst target price relative to current price) than 85.25% of all US stocks.
- Innate Pharma SA's average analyst price target is higher than 16.67% of all US stocks.
- IPHA has a greater number of analysts covering the stock than 78.48% of stocks in the small market cap category.
Is IPHA a Buy, Hold or Sell? See the POWR Ratings now!